Amgen Report on Nuzzel

fool.com - Todd Campbell - Is Now a Good Time to Buy Amgen?

Is Now a Good Time to Buy Amgen?

The Motley Fool – Todd Campbell
amgenteach.eu - About | Amgen Teach

About | Amgen Teach

Amgen Teach
xconomy.com - Frank Vinluan - Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen's

Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen's

Xconomy – Frank Vinluan
biospace.com - Mark Terry - Morgan Stanley Global Healthcare Conference Update: Lilly, Amgen and Biogen

Morgan Stanley Global Healthcare Conference Update: Lilly, Amgen and Biogen

BioSpace – Mark Terry
breakawayfromcancer.com - Amgen

Amgen

Amgen
myelomacrowd.org - Amgen Advances the Immunotherapy Race in Multiple Myeloma

Amgen Advances the Immunotherapy Race in Multiple Myeloma

The Myeloma Crowd
fiercebiotech.com - Amgen to consolidate its digital patient engagement systems under Deloitte banner

Amgen to consolidate its digital patient engagement systems under Deloitte banner

FierceBiotech
statnews.com - Adam Feuerstein - Amgen emerges as a multiple myeloma drug player, threatening Bluebird, Celgene

Amgen emerges as a multiple myeloma drug player, threatening Bluebird, Celgene

STAT – Adam Feuerstein
corporate-ir.net - Amgen - Investors - RSS Content

Amgen - Investors - RSS Content

corporate-ir.net

Top Sources reporting on Amgen

Name
1 aktiencheck.de
2 Wall Street Morning
3 Endpoints News
4 Seeking Alpha
5 Cyclingnews.com
6 EIN News
7 PR Newswire